Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort single inhaler therapy in mild to moderate asthma
NCT00235911Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2003
- Primary completion
- Oct 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide in asthma, sponsored by AstraZeneca. Primary endpoint: Change in PD20 histamine. Started Sep 2003; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00235911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00235911.